Amryt Pharma (Amryt Pharma) Short-Term Debt & Capital Lease Obligation : $1.0 Mil (As of Sep. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Amryt Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $1.0 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Amryt Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $211.8 Mil.

Amryt Pharma Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Amryt Pharma's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Short-Term Debt & Capital Lease Obligation Chart

Amryt Pharma Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

0.57

Amryt Pharma Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															1.53	-	0.96	6.63	0.97

Amryt Pharma Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Amryt Pharma Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Amryt Pharma (Amryt Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH

Website

http://www.amrytpharma.com

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).